For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GJM865. CME/MOC/AAPA/IPCE credit will be available until March 12, 2025.
A Joint Effort for Equitable Hemophilia A Care: Collaborative Solutions for Enhancing Outcomes in Diverse and Challenging Patient Populations
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by educational grants from Genentech, a member of the Roche Group, and Novo Nordisk Inc.
Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Amy Shapiro, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Be Biopharma; BioMarin; Genentech, Inc./F. Hoffmann-La Roche Ltd; HEMA Biologics, LLC; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; and Sanofi-Genzyme.
Grant/Research Support from Agios Pharmaceuticals, Inc.; BioMarin; Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi-Genzyme; Pharmacosmos A/S; and Takeda Pharmaceutical Company Limited.
Speakers Bureau participant with Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; and Sanofi-Genzyme.
Other Financial or Material Support in the form as a board member of the Novo Nordisk Haemophilia Foundation. She is the Medical Director of the National Hemophilia Program and Coordinating Center of the American Thrombosis Hemostatis Network.
Faculty/Planner
Maissaa Janbain, MD, MSCR, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Clovis Oncology, Inc.; Genentech, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; Sanofi Genzyme; and Seagen Inc.
Grant/Research Support from AstraZeneca; Pfizer; and Seagen Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Robert Z. Orlowski, MD, PhD - Building Real-World Bridges Between Clinicians and Patients With Myeloma: Guidance on Innovative Antibody Options
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Anthony R. Mato, MD, MSCE - Upgrading the Sequential Therapy Tool Kit for B-Cell Malignancies: New Evidence on the Individualized Use of BTK Inhi
Sagar Lonial, MD, FACP - Navigating From A to B and C in Multiple Myeloma: Delivering High-Quality Care With mAbs, BCMA ADCs, and Cellular Therapy
Jason Westin, MD, MS, FACP - Rising to the Occasion: Improving Outcomes in Leukemia, Lymphoma, and Multiple Myeloma With CAR T-Cell Therapy in Community Practice
Anthony R. Mato, MD, MSCE - Rewriting the Treatment Script in CLL: Guidance on Integrating Modern Targeted and Next-Gen Options Into Patient Care
Prof. Dr. med. Stephan Stilgenbauer - New Rules for BTK Inhibitors in CLL: Benchmarks for Evidence-Based Treatment Selection, Sequencing, and Safety Management
Luke Maese, DO - Applying Therapeutic Innovations Against ALL: From Updated Evidence to Everyday Practice
Nina Shah, MD - The "Myelennial" Generation: Managing the Boom of Innovative Therapy to Transform Myeloma Care and Enhance Patient Outcomes
Gail J. Roboz, MD - The Advantage of Innovation in AML: Guidance on Developing and Delivering Effective and Highly Personalized Care
David P. Carbone, MD, PhD - Gaining an Advantage Over NSCLC: How to Achieve the Greatest Benefit With Immunotherapy From Advanced to Early Disease
Stuart S. Winter, MD - Adapting to Innovation in Pediatric ALL: Guidance on Optimizing Modern Therapy and the Role of Novel Asparaginase Compounds
Zev A. Wainberg, MD - Targeting TIGIT to Extend Immunotherapy Benefits to More Cancer Patients: A Strategy to Amplify Immune Response and Enhance or Restore Antitumor Activity
James M. Foran, MD, FRCPC - Landmarks Across the Patient Journey in AML: Applying Evidence With Novel Therapeutics Pre- and Post-AlloHCT
Michael R. Bishop, MD - CAR-T Cell Therapy: Are You Up to the Challenge? New Evidence and Best Practices Driving Modern Cellular Therapies as a Standard of Care for Leukemia and Lymphoma
Stephen V. Liu, MD - Find the Targets, Treat With Precision: Modern Principles and New Advances in Biomarker-Driven Lung Cancer Care
Bruce R. Korf, MD, PhD - Revolutionizing the Standard of NF1 Care: Insights on Innovative MEK-Inhibitor Options for NF1-Associated PNs
Nasser Altorki, MD - How to Integrate Perioperative Immunotherapy Into Multimodal Treatment Plans to Improve Outcomes in Resectable NSCLC
Prof. Solange Peters, MD, PhD - Parsing the Practicalities of Pathologic Response Assessment After Neoadjuvant Immunotherapy to Facilitate Progress in Early-Stage Cancers
Linda Ahn, MSN, ANP-BC, AOCNP - Tackling the Practicalities of Antibody–Drug Conjugate Therapy for Solid Tumors: Improving Clinical Care With HER2-, HER3-, and TROP2-Targeted Therapies
Jonathan Corren, MD - Airway Inflammation Isn’t the Only Problem: Shining a Light on the Role of Airway Hyper-Responsiveness in Severe Asthma
Create your
podcast in
minutes
It is Free
PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast
PeerView Internal Medicine CME/CNE/CPE Audio Podcast
PeerView Endocrinology & Diabetes CME/CNE/CPE Audio Podcast
PeerView Neuroscience & Psychiatry CME/CNE/CPE Video Podcast
PeerView Gastroenterology CME/CNE/CPE Audio Podcast